Published in Biochem Pharmacol on September 28, 1995
Structure of the topoisomerase II ATPase region and its mechanism of inhibition by the chemotherapeutic agent ICRF-187. Proc Natl Acad Sci U S A (2003) 1.44
Mammalian Fbh1 is important to restore normal mitotic progression following decatenation stress. DNA Repair (Amst) (2010) 0.91
Iron chelators with topoisomerase-inhibitory activity and their anticancer applications. Antioxid Redox Signal (2012) 0.91
Dexrazoxane ameliorates doxorubicin-induced injury in mouse ovarian cells. Biol Reprod (2012) 0.89
Integrating molecular docking, DFT and CoMFA/CoMSIA approaches for a series of naphthoquinone fused cyclic α-aminophosphonates that act as novel topoisomerase II inhibitors. J Mol Model (2010) 0.79
Differential expression of topoisomerase I and RAD52 protein in yeast reveals new facets of the mechanism of action of bisdioxopiperazine compounds. Br J Cancer (1999) 0.79
Induction of thrombospondin-1 partially mediates the anti-angiogenic activity of dexrazoxane. Br J Cancer (2009) 0.79
Structure-based design, synthesis and biological testing of etoposide analog epipodophyllotoxin-N-mustard hybrid compounds designed to covalently bind to topoisomerase II and DNA. Bioorg Med Chem (2014) 0.78
Dexrazoxane for the treatment of chemotherapy-related side effects. Cancer Manag Res (2014) 0.76
The effect of the catalytic topoisomerase II inhibitor dexrazoxane (ICRF-187) on CC9C10 hybridoma viability and productivity. Cytotechnology (2001) 0.75
Statins in anthracycline-induced cardiotoxicity: Rac and Rho, and the heartbreakers. Cell Death Dis (2017) 0.75
A topoisomerase II-dependent G2 cycle checkpoint in mammalian cells/. Nature (1994) 2.35
Antitumour activity in a series of bisdiketopiperazines. Nature (1969) 1.89
Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells. Mol Pharmacol (1994) 1.88
Rapid formation of poly-gamma-glutamyl derivatives of methotrexate and their association with dihydrofolate reductase as assessed by high pressure liquid chromatography in the Ehrlich ascites tumor cell in vitro. J Biol Chem (1982) 1.52
Atypical multiple drug resistance in a human leukemic cell line selected for resistance to teniposide (VM-26). Cancer Res (1987) 1.44
Mutational inactivation of the p53 gene in the human erythroid leukemic K562 cell line. Leuk Res (1993) 1.40
Metallothionein protects against the cytotoxic and DNA-damaging effects of nitric oxide. Proc Natl Acad Sci U S A (1995) 1.37
Pro-oxidant and antioxidant mechanisms of etoposide in HL-60 cells: role of myeloperoxidase. Cancer Res (2001) 1.15
The histone deacetylase inhibitor sodium butyrate induces DNA topoisomerase II alpha expression and confers hypersensitivity to etoposide in human leukemic cell lines. Mol Cancer Ther (2001) 1.08
Altered stability of etoposide-induced topoisomerase II-DNA complexes in resistant human leukaemia K562 cells. Br J Cancer (1994) 1.07
Cytoplasmic metallothionein overexpression protects NIH 3T3 cells from tert-butyl hydroperoxide toxicity. J Biol Chem (1994) 1.04
Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines. Cancer Res (1998) 0.98
Collateral sensitivity to the bisdioxopiperazine dexrazoxane (ICRF-187) in etoposide (VP-16)-resistant human leukemia K562 cells. Biochem Pharmacol (1996) 0.97
Chromosomal and extrachromosomal instability of the cyclin D2 gene is induced by Myc overexpression. Neoplasia (1999) 0.97
The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces differentiation and apoptosis in human leukemia K562 cells. Mol Pharmacol (2001) 0.96
Phenoxyl radicals of etoposide (VP-16) can directly oxidize intracellular thiols: protective versus damaging effects of phenolic antioxidants. Toxicol Appl Pharmacol (1995) 0.95
Probing the interaction of the cytotoxic bisdioxopiperazine ICRF-193 with the closed enzyme clamp of human topoisomerase IIalpha. Mol Pharmacol (2000) 0.94
Potentiation of etoposide-induced DNA damage by calcium antagonists in L1210 cells in vitro. Cancer Res (1984) 0.94
Proceedings: Mechanism of action studies with IRCF 159: effects on the growth and morphology of BHK-21S cells. Br J Cancer (1974) 0.93
Verapamil-induced augmentation of etoposide accumulation in L1210 cells in vitro. Cancer Res (1985) 0.91
Rapid determination of thymidylate synthase activity and its inhibition in intact L1210 leukemia cells in vitro. Biochem Pharmacol (1985) 0.90
Mutations at the stromal processing peptidase cleavage site of a thylakoid lumen protein precursor affect the rate of processing but not the fidelity. J Biol Chem (1994) 0.89
Transforming growth factor-beta1 stimulates multiple protein interactions at a unique cis-element in the 3'-untranslated region of the hyaluronan receptor RHAMM mRNA. J Biol Chem (1996) 0.89
Reduced phosphorylation of topoisomerase II in etoposide-resistant human leukemia K562 cells. Mol Pharmacol (1994) 0.89
Differential induction of etoposide-mediated apoptosis in human leukemia HL-60 and K562 cells. Mol Pharmacol (1994) 0.88
Altered gene expression in human leukemia K562 cells selected for resistance to etoposide. Biochem Pharmacol (1993) 0.86
Mechanism-based chemopreventive strategies against etoposide-induced acute myeloid leukemia: free radical/antioxidant approach. Mol Pharmacol (1999) 0.86
Nitric oxide prevents oxidative damage produced by tert-butyl hydroperoxide in erythroleukemia cells via nitrosylation of heme and non-heme iron. Electron paramagnetic resonance evidence. J Biol Chem (1997) 0.85
Mitindomide is a catalytic inhibitor of DNA topoisomerase II that acts at the bisdioxopiperazine binding site. Mol Pharmacol (1997) 0.85
Characterization of a Chinese hamster ovary cell line with acquired resistance to the bisdioxopiperazine dexrazoxane (ICRF-187) catalytic inhibitor of topoisomerase II. Biochem Pharmacol (1997) 0.85
Ascorbate is the primary reductant of the phenoxyl radical of etoposide in the presence of thiols both in cell homogenates and in model systems. Biochemistry (1994) 0.85
Increased c-jun/AP-1 levels in etoposide-resistant human leukemia K562 cells. Biochem Pharmacol (1994) 0.85
Effects of verapamil on etoposide, vincristine, and adriamycin activity in normal human bone marrow granulocyte-macrophage progenitors and in human K562 leukemia cells in vitro. Cancer Res (1985) 0.84
Antioxidant mechanisms of nitric oxide against iron-catalyzed oxidative stress in cells. Antioxid Redox Signal (2001) 0.84
Synthesis and biological activity of a photoaffinity etoposide probe. Bioorg Med Chem (2001) 0.84
Differentiation of U-937 promonocytic cells by etoposide and ICRF-193, two antitumour DNA topoisomerase II inhibitors with different mechanisms of action. J Cell Sci (1997) 0.83
Chemistry of dexrazoxane and analogues. Semin Oncol (1998) 0.83
The effect of dexrazoxane (ICRF-187) on doxorubicin- and daunorubicin-mediated growth inhibition of Chinese hamster ovary cells. Anticancer Drugs (1996) 0.83
Radioactive labeling of recombinant antibody fragments by phosphorylation using human casein kinase II and [gamma-32P]-ATP. Nat Biotechnol (1996) 0.83
The cardioprotective and DNA topoisomerase II inhibitory agent dexrazoxane (ICRF-187) antagonizes camptothecin-mediated growth inhibition of Chinese hamster ovary cells by inhibition of DNA synthesis. Anticancer Drugs (1999) 0.82
Pharmacodynamics of the hydrolysis-activation of the cardioprotective agent (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane. J Pharm Sci (1994) 0.82
The protective activity of ICRF-187 against doxorubicin-induced cardiotoxicity in the rat. Cancer Chemother Pharmacol (1992) 0.82
Analysis of the inhibitory effects of VP-16-213 (etoposide) and podophyllotoxin on thymidine transport and metabolism in Ehrlich ascites tumor cells in vitro. Cancer Res (1984) 0.80
Recombinant anti-human melanoma antibodies are versatile molecules. J Invest Dermatol (1996) 0.80
Myc-induced cyclin D2 genomic instability in murine B cell neoplasms. Curr Top Microbiol Immunol (1999) 0.80
The one-ring open hydrolysis intermediates of the cardioprotective agent dexrazoxane (ICRF-187) do not inhibit the growth of Chinese hamster ovary cells or the catalytic activity of DNA topoisomerase II. Anticancer Drugs (1998) 0.79
Biochemical studies on growth-inhibitory bisdioxopiperazines. I. Effect on DNA, RNA and protein synthesis in mouse-embryo fibroblasts. Int J Cancer (1970) 0.79
Deregulated expression of c-Myc in a translocation-negative plasmacytoma on extrachromosomal elements that carry IgH and myc genes. Proc Natl Acad Sci U S A (1999) 0.79
Differential expression of topoisomerase I and RAD52 protein in yeast reveals new facets of the mechanism of action of bisdioxopiperazine compounds. Br J Cancer (1999) 0.79
Interactions of phenoxyl radical of antitumor drug, etoposide, with reductants in solution and in cell and nuclear homogenates: electron spin resonance and high-performance liquid chromatography. Methods Enzymol (1994) 0.79
Direct evidence for recycling of myeloperoxidase-catalyzed phenoxyl radicals of a vitamin E homologue, 2,2,5,7,8-pentamethyl-6-hydroxy chromane, by ascorbate/dihydrolipoate in living HL-60 cells. Biochim Biophys Acta (2003) 0.79
Genesis of discrete higher order DNA fragments in apoptotic human prostatic carcinoma cells. Mol Pharmacol (1996) 0.78
The enzymatic hydrolysis-activation of the adriamycin cardioprotective agent (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane. Drug Metab Dispos (1991) 0.78
Characteristics of the accumulation of methotrexate polyglutamate derivatives in Ehrlich ascites tumor cells and isolated rat hepatocytes. Adv Exp Med Biol (1983) 0.78
P-glycoprotein mediates profound resistance to bisantrene. Oncol Res (1994) 0.78
Chemical synthesis and biological activity of a novel fluorescent etoposide derivative. Biochem Pharmacol (1997) 0.78
Induction of human breast cancer cell apoptosis from G2/M preceded by stimulation into the cell cycle by Z-1,1-dichloro-2,3-diphenylcyclopropane. Biochem Pharmacol (1999) 0.77
The removal of metal ions from transferrin, ferritin and ceruloplasmin by the cardioprotective agent ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane] and its hydrolysis product ADR-925. Agents Actions (1993) 0.77
Augmentation of the intracellular levels of polyglutamyl derivatives of methotrexate by vincristine and probenecid in Ehrlich ascites tumor cells. Cancer Res (1982) 0.77
Metal binding by pharmaceuticals. Part 2. Interactions of Ca(II), Cu(II), Fe(II), Mg(II), Mn(II) and Zn(II) with the intracellular hydrolysis products of the antitumour agent ICRF 159 and its inactive homologue ICRF 192. Agents Actions (1982) 0.77
Myeloperoxidase-catalyzed phenoxyl radicals of vitamin E homologue, 2,2,5,7,8-pentamethyl- 6-hydroxychromane, do not induce oxidative stress in live HL-60 cells. Biochem Biophys Res Commun (2000) 0.77
Stereoselective hydrolysis of ICRF-187 (dexrazoxane) and ICRF-186 by dihydropyrimidine amidohydrolase. Chirality (1994) 0.77
Metal binding by pharmaceuticals. Part 5. Interaction of Cd(II), Ni(II) and Pb(II) with the intracellular hydrolysis products of the anti-tumour agent ICRF 159 and its inactive homologue ICRF 192. Agents Actions (1984) 0.77
The effect of bisdioxopiperazines on the synthesis of deoxyribonucleic acid, ribonucleic acid and protein in growing mouse-embryo fibroblasts. Biochem J (1969) 0.77
The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces endopolyploidy in Chinese hamster ovary cells. J Pharmacol Exp Ther (2000) 0.77
Induction of apoptosis in murine and human neuroblastoma cell lines by the enediyne natural product neocarzinostatin. J Pharmacol Exp Ther (1995) 0.76
Hypophosphorylation of topoisomerase II in etoposide (VP-16)-resistant human leukemia K562 cells associated with reduced levels of beta II protein kinase C. Mol Pharmacol (1995) 0.76
Comparison of the protective effect of ICRF-187 and structurally related analogues against acute daunorubicin toxicity in Syrian golden hamsters. Res Commun Chem Pathol Pharmacol (1985) 0.76
Effects of microtubule inhibitors on etoposide accumulation and DNA damage in human K562 cells in vitro. Cancer Res (1987) 0.76
Non-random peroxidation of different classes of membrane phospholipids in live cells detected by metabolically integrated cis-parinaric acid. Biochim Biophys Acta (1996) 0.76
ICRF 159-induced cell-cycle perturbation in vitro: its relationship to inhibition of colony-forming ability. Br J Cancer (1981) 0.75
Conjugation of monoclonal antibodies to a synthetic peptide substrate for protein kinase: a method for labelling antibodies with 32P. Br J Cancer (1988) 0.75
A cis-trans interaction at the 3'-untranslated region of ribonucleotide reductase mRNA is regulated by TGF-beta 1, TGF-beta 2, and TGF-beta 3. Biochem Biophys Res Commun (1996) 0.75
Quantitation of the dexrazoxane hydrolysis product ADR-925 by fluorescence detection of its terbium(III) complex after high-performance liquid chromatographic separation. J Chromatogr B Biomed Appl (1994) 0.75
Leukaemia associated with razoxane. Lancet (1982) 0.75
Expression of protein-associated DNA damage in the alkaline elution assay in the absence of enzymatic deproteinization. Cancer Commun (1989) 0.75
Inheritance of cellular resistance to the antitumor agent ICRF 159 in somatic cell hybrids. J Natl Cancer Inst (1982) 0.75
Increased mutant frequencies in the HPRT gene locus of leukemia HL-60 cells treated with succinylacetone. Cell Biol Toxicol (2006) 0.75
Enzymatic ring-opening reactions of the chiral cardioprotective agent (+) (S)-ICRF-187 and its (-) (R)-enantiomer ICRF-186 by dihydropyrimidine amidohydrolase. Drug Metab Dispos (1993) 0.75
Letter: ICRF 159. Lancet (1974) 0.75
Metabolism of the cardioprotective agents dexrazoxane (ICRF-187) and levrazoxane (ICRF-186) by the isolated hepatocyte. Xenobiotica (1994) 0.75
Teniposide (VM-26)- and etoposide (VP-16-213)-induced augmentation of methotrexate transport and polyglutamylation in Ehrlich ascites tumor cells in vitro. Cancer Res (1982) 0.75
Efficient but aberrant cleavage of mitochondrial precursor proteins by the chloroplast stromal processing peptidase. Eur J Biochem (1994) 0.75